Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,099 public trials 2,041 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

NCT00585195

Conditions
Advanced Malignancies Except Leukemia, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • University of California, Irvine Medical Center Orange, California, United States
  • University of Colorado Hospital/ Anschutz Cancer Pavilion Aurora, Colorado, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • University of Colorado Aurora, Colorado, United States
View all 29 locations
View Trial Details
Completed

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

NCT02743351

Conditions
Acute Graft-versus-host Disease, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, +35 more
Locations
  • University of Alabama Birmingham, Alabama, United States
  • City of Hope Duarte, California, United States
  • University of California, San Diego (UCSD) Moores Cancer Center San Diego, California, United States
  • University of Chicago Chicago, Illinois, United States
View all 15 locations
View Trial Details
Completed

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

NCT03357627

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Emory University Atlanta, Georgia, United States
  • NorthShore Medical Group - Evanston Evanston, Illinois, United States
  • Ingalls Memorial Hospital Harvey, Illinois, United States
View all 15 locations
View Trial Details
Completed

Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT03476239

Conditions
Acute Lymphoblastic Leukemia, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Chinese People Liberation Army General Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
View all 23 locations
View Trial Details

Related conditions